Profile data is unavailable for this security.
About the company
Nxera Pharma Co Ltd, formerly known as Sosei Group Corp, is a Japan-based company engaged in the biopharmaceutical business that handles from drug research (drug discovery) to development and sale. The Company is mainly engaged in the pharmaceutical business. The Company is engaged in drug discovery, translational medicine, preclinical and early clinical development, as well as the research and development, import/export, packaging, and sale of pharmaceuticals. The Company also conducts structural analysis of G protein-coupled receptors (GPCRs), creates initial lead compounds, and searches for candidate products using StaR technology.
- Revenue in JPY (TTM)28.70bn
- Net income in JPY-6.14bn
- Incorporated1990
- Employees374.00
- LocationNxera Pharma Co Ltd7f, Midtown East, 9-7-2, AkasakaMINATO-KU 107-0052JapanJPN
- Phone+81 359625718
- Fax+81 352103291
- Websitehttps://www.nxera.life/
More ▼
Mergers & acquisitions
| Acquired company | 4565:TYO since announced | Transaction value |
|---|---|---|
| Santhera Pharmaceuticals Holding AG - Agamree (Vamorolone) | -1.92% | 205.00m |
Data delayed at least 15 minutes, as of Feb 13 2026 06:30 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daito Pharmaceutical Co Ltd | 51.20bn | 2.23bn | 41.23bn | 1.07k | 18.41 | 0.7768 | 6.22 | 0.8053 | 74.42 | 74.42 | 1,703.91 | 1,763.62 | 0.6544 | 2.16 | 2.76 | 47,716,680.00 | 2.90 | 5.12 | 3.71 | 6.67 | 17.63 | 21.75 | 4.43 | 7.35 | 1.31 | -- | 0.1739 | 24.48 | 7.99 | 2.39 | -42.09 | -13.52 | 20.45 | 14.00 |
| Fuji Pharma Co Ltd | 54.57bn | 2.33bn | 56.30bn | 1.76k | 23.70 | 1.15 | 8.95 | 1.03 | 95.46 | 95.46 | 2,233.29 | 1,959.48 | 0.5765 | 1.49 | 2.83 | 31,007,950.00 | 2.46 | 4.51 | 3.93 | 6.76 | 40.82 | 40.57 | 4.27 | 8.51 | 0.876 | 17.58 | 0.3885 | 25.98 | 12.01 | 8.87 | -51.19 | 7.55 | 8.07 | 7.94 |
| Oncolys Biopharma Inc | 28.55m | -2.06bn | 64.21bn | 35.00 | -- | 16.04 | -- | 2,249.25 | -80.66 | -80.66 | 1.11 | 136.64 | 0.0074 | 0.00 | 0.1004 | -- | -53.08 | -53.26 | -58.54 | -60.19 | 0.00 | -- | -7,209.58 | -484.93 | 9.54 | -424.60 | 0.0741 | -- | -9.04 | -38.10 | -22.16 | -- | 2.22 | -- |
| Cuorips Inc | 360.02m | -661.72m | 69.93bn | 56.00 | -- | 13.31 | -- | 194.23 | -81.32 | -81.32 | 44.45 | 635.67 | 0.0642 | 3.87 | 247.60 | 6,428,875.00 | -11.85 | -- | -12.15 | -- | 77.23 | -- | -184.50 | -- | 42.03 | -- | 0.00 | -- | 658.40 | -- | -1.92 | -- | -- | -- |
| ASKA Pharmaceutical Holdings Co Ltd | 68.70bn | 4.91bn | 69.98bn | 1.63k | 14.07 | 1.01 | 9.03 | 1.02 | 172.92 | 172.92 | 2,421.07 | 2,420.68 | 0.6729 | 1.37 | 3.62 | 42,094,980.00 | 4.93 | 5.50 | 6.64 | 7.07 | 48.33 | 47.56 | 7.32 | 7.98 | 1.23 | 75.35 | 0.1551 | 16.60 | 2.06 | 4.07 | -32.39 | 51.04 | 9.49 | 31.48 |
| Nxera Pharma Co Ltd | 28.70bn | -6.14bn | 79.28bn | 374.00 | -- | 1.21 | -- | 2.76 | -68.13 | -68.13 | 318.44 | 725.52 | 0.1936 | 1.47 | 4.57 | 76,737,970.00 | -4.14 | -1.71 | -4.63 | -1.85 | 71.17 | 84.07 | -21.41 | -10.93 | 2.55 | -11.73 | 0.4902 | -- | 125.87 | 24.28 | 32.74 | -- | 40.57 | -- |
| JCR Pharmaceuticals Co Ltd | 37.55bn | -2.44bn | 86.37bn | 987.00 | -- | 1.75 | 185.74 | 2.30 | -19.98 | -19.98 | 307.86 | 379.76 | 0.3432 | 0.4534 | 2.50 | 38,039,510.00 | -2.21 | 5.86 | -3.77 | 9.33 | 70.45 | 73.83 | -6.45 | 13.60 | 0.668 | -- | 0.5295 | 45.13 | -22.86 | 5.94 | -186.42 | -- | 15.37 | 20.11 |
| Kyorin Pharmaceutical Co Ltd | 133.26bn | 10.77bn | 100.11bn | 2.00k | 8.91 | 0.6908 | 6.51 | 0.7513 | 187.40 | 187.40 | 2,319.59 | 2,417.37 | 0.6927 | 1.08 | 2.93 | 66,695,200.00 | 5.60 | 3.34 | 7.03 | 4.16 | 45.32 | 45.89 | 8.08 | 5.11 | 2.05 | -- | 0.1746 | 57.34 | 8.83 | 3.41 | 70.73 | 8.12 | 14.36 | -7.06 |
| Katakura Industries Co Ltd | 40.98bn | 5.84bn | 110.75bn | 941.00 | 17.25 | 1.10 | 12.59 | 2.70 | 182.30 | 182.30 | 1,278.51 | 2,853.06 | 0.2926 | 2.15 | 6.42 | 43,545,160.00 | 4.27 | 2.60 | 5.20 | 3.57 | 36.16 | 37.98 | 14.59 | 9.44 | 2.63 | -- | 0.0807 | 23.42 | -1.37 | -2.19 | 15.73 | 15.27 | -7.22 | 33.03 |
| Zeria Pharmaceutical Co Ltd | 86.61bn | 7.26bn | 113.13bn | 1.75k | 13.43 | 1.02 | 7.77 | 1.31 | 164.79 | 164.79 | 1,964.97 | 2,178.21 | 0.5366 | 1.27 | 3.21 | 49,607,640.00 | 4.49 | 4.67 | 6.99 | 7.47 | 72.76 | 72.17 | 8.37 | 9.02 | 0.9739 | 11.41 | 0.2984 | 28.75 | 15.30 | 7.64 | 28.52 | 27.71 | 16.51 | 6.69 |
Data as of Feb 13 2026. Currency figures normalised to Nxera Pharma Co Ltd's reporting currency: Japanese Yen JPY
21.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Taiyo Pacific Partners LPas of 18 Jun 2025 | 4.35m | 4.80% |
| Nomura Asset Management Co., Ltd.as of 31 Jul 2024 | 3.85m | 4.26% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.71m | 3.00% |
| Asset Management One Co., Ltd.as of 15 Jan 2026 | 1.63m | 1.81% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 08 Jan 2026 | 1.58m | 1.75% |
| Amova Asset Management Co., Ltd.as of 09 Jan 2026 | 1.27m | 1.41% |
| BlackRock Fund Advisorsas of 08 Jan 2026 | 1.26m | 1.40% |
| Daiwa Asset Management Co. Ltd.as of 30 Dec 2025 | 1.25m | 1.38% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 1.12m | 1.24% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 772.00k | 0.85% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
